A new physiopathological classification of diabetic neuropathy;Bases fisiopatológicas para una clasificación de la neuropatía diabética

Revista Medica de Chile

Volumn 140, Issue 12, 2012, Pages 1593-1605

  Olmos, Pablo R ^a,b   Niklitschek, Sergio ^b   Olmos, Roberto I ^b   Faúndez, Jorge I ^b   Quezada, Thomas A ^b   Bozinovic, Milan A ^b   Niklitschek, Ian A ^b   Acosta, Jorge ^b   Valencia, Claudio N ^a   Bravo, Felipe A ^a  

^a Centro de Estudios en Hidro Electrometalurgia   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Diabetes complications; Diabetic neuropathies; Physiopathology

Indexed keywords

EID: 84877659080     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/s0034-98872012001200012     Document Type: Review

References (43)

1. Said G, Baudoin D, Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol 2008; 255: 1693-702.
2. Sima AAF. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 1-20.
3. Skljarevski V. Historical aspects of diabetic neuropathies. En: Veves A, Malik RA, Editors. Diabetic neuropathy, clinical management. 2007 by Humana Press Inc., New Jersey, USA. Páginas 1-5.
4. Tracy JA, Dick PJB. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am 2008; 19 (1): 1-26. Doi:10.1016/j.pmr.2007.10.010.
5. Yasuda H, Terada M, Maeda K, Kogawa S, Sanada M, Haneda M, et al. Diabetic neuropathy and nerve regeneration. Progress in Neurobiology 2003; 69: 229-85.
6. Iribarren B, Passi G, Aybar N, Ríos P, González L, Rojas MA, Saavedra F. Pie diabético: Evolución de una serie de 121 pacientes. Rev Chilena de Cirugía 2007; 59 (5): 337-41.
7. Adler AI, Erqou S, Lima TAS, Robinson AHN. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. Diabetologia 2010; 53: 840-9.
8. Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011; 4: 289-305.
9. Eastman RC. Chapter 15: Neuropathy in Diabetes. En: Diabetes in America, 2nd Edition. National Diabetes Data Group. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication N° 95-1468. Año 1995. Páginas 339-48.
10. Sinnreich M, Taylor BV, Dick PJ. Diabetic neuropathies: Classification, clinical features and pathophysiological basis. The Neurologist 2005; 11: 63-79.
11. Bastías MJ; Toro L; Olmos P. La insulinoterapia intensificada más antineuríticos es superior a antineurítico puro en neuropatía diabética dolorosa. Rev Med Chile 2006; 134 (12): 1507-15.
12. Tracy JA, Engelstad JK, Dyck PJB. Microvasculitis in diabetic lumbosacral radiculoplexus neuroipathy. J Clin Neuromuscul Dis 2009; 11 (1): 44-8.
13. Myers RR. Anatomy and microanatomy of peripheral nerve. Neurosurg Clin N Am. 1991; 2 (1): 1-20.
14. Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, et al. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 2003; 14: S259-63.
15. Monnier VM, Cerami A. Nonenzymatic browning in vivo: Possible process for aging in long-lived proteins. Science 1981; 211: 491-4.
16. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53: 131-42.
17. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-16.
18. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diab Res Clin Pract 2005; 67: 3-21.
19. Ahmed N, Thornalley PJ. Advanced glycation endproducts: What is their relevance to diabetic complications?. Diab Obes Metab 2007; 9: 233-45.
20. Stern DM, Yan SD, Yan SF, Schmidt A-M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Age Res Rev 2002; 1-15.
21. Wolff SP. Transition metals and oxidative stress in the complications of diabetes. En: Gries FA, Wessel K., editors. The role of antioxidants in diabetes mellitus. ©1993 por Universimed Verlag, Frankfurt am Main, Alemania, páginas 82-101.
22. Diano S, Horvath TL. A sympathetic view on free radicals in diabetes. Neuron 2010; 37: 809-811; DOI 10.1016/j.neuron.2010.06.011.
23. Atwal JK, Massie B, Miller FD, Kaplan DR. The TrkB-Shc Site Signals Neuronal Survival and Local Axon Growth via MEK and PI3-Kinase. Neuron 2000; 27: 265-77.
24. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. (2000) 351: 289-305.
25. Roux PP, Bhakar AL, Kennedy TE, Barkeri PA. The p75 Neurotrophin Receptor Activates Akt (Protein Kinase B) through a Phosphatidylinositol 3-Kinase-dependent Pathway. The Journal of Biological Chemistry 2001; 276 (25): 23097-104.
26. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 15 (351 pt 2): 289-305.
27. Nishina H, Wada T, Katada T. Physiological Roles of SAPK/JNK Signaling Pathway. J Biochem 2004; 136 (2): 123-6.
28. Timperley WR, Preston FE, Ward JD. Cerebral intravascular coagulation in diabetic ketoacidosis. Lancet 1974; 1 (7864): 952-956 [PubMed: 4133643].
29. Caravati CM. Insulin neuritis: a case report. Va Med Monthly 1933; 59: 745-6.
30. Gibbons CH, Freeman R. Treatment induced diabetic neuropathy-a reversible painful autonomic neuropathy. Ann Neurol 2010; 64 (4): 534-41. Doi:10.1002/ana.21952.
31. Kihara M, Zollman PJ, Smithson IL, Lagerlund TD, Low PA. Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. Am J Physiol 1994; 266 (6 pt 1): E980-5.
32. Tesfaye S, Mailk R, Harris N, Jakubowski JJ, Mody C, Rennie IG, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuriris). Diabetologia 1996; 39 (3): 329-35.
33. Sima AA, Zhang WX, Greene DA. Diabetic and hypoglycemic neuropathy-a comparison in the BB rat. Diabetes Res Clin Pract 1989; 6 (4): 279-96.
34. Niemeyer H. Capítulo 12 Metabolismo de los hidratos de carbono. En: Niemeyer H. Bioquímica. 2° Edición 1978 por Editorial Inter-Médica S.A.I.C.I., Buenos Aires, República Argentina. Páginas 33-63.
35. Nelson DL, Cox MM. Glycolysis, gluconeogenesis and the pentose phosphate pathway. In: Nelson DL, Cox MM, Editors. Leninger: Principles of Biochemistry. 5th Edition 2008 by W. H. Freeman and Company, New York, U.S.A. Pages 550-1.
36. Beltramo E, Berrone E, Tarallo S, Porta M. Effects of thiamine and benfotiamine on intracelular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 2008; 45: 131-41.
37. Igata A. Clinical studies on rising and re-rising neurological diseases in Japan. Proc Jpn Acad 2010; Ser B 86: 366-76.
38. Olmos P, Araya-Del-Pino A, González C, Laso P, Irribarra V, Rubio L. Fisiopatología de la retinopatía y nefropatía diabéticas. Rev Med Chile 2009; 137: 1375-84.
39. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharm Res 2010; 61: 482-8.
40. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005; 1 (3): 287-98.
41. Page GLJ, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus, and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract 2011; 65 (6): 684-90.
42. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al, Fr the DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab rep 2010; 10: 276-82.
43. Colagiuri S. Optimal management of type 2 diabetes: the evidence. Diab Obes Metab 2012; 14 (suppl. 1): 3-8. DOI: 10.1111/j.1463-1326.2011.01506.x